National Institute for Clinical Excellence (NICE) guidance endorsed Coralan® for the management of heart failure patients

Once again Coralan® (Ivabradine) is at the forefront of international recommendations. After the new European Society of Cardiology Guidelines, today the National Institute for Clinical Excellence (NICE) guidance endorses Coralan for the management of heart failure patients.

The NICE guidance recognizes ivabradine as an option for the treatment of people with chronic heart failure (NYHA classes II to IV) with systolic dysfunction, who are in sinus rhythm and whose heart rate is 75 bpm or more and who have an LV ejection fraction of 35% or less.

Aim of heart failure is to improve life expectancy, quality of life and also avoid hospitalization. This is where Coralan excels. Addition of Coralan on top of standard therapy, has been proven to increase survival rate, give better quality of life and reduce frequency and length of hospitalization.

Coralan works by lowering the heart rate exclusively. It is to be given on top of standard therapy, which might include beta blockers.

 

Author
Pratiwi Utari
Medical Information Project Manager
 
Source
Böhm M, et al. Clin Res Cardiol. 2012;102:1‐12; Borer JS et al. Eur Heart J Online, 27  August 2012; Ekman I et al. Eur Heart J. 2011;32(19):2395-404